Are you Dr. Bhalla?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 56 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-745-1782- Is this information wrong?
Summary
- Dr. Kapil Bhalla, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Georgia. He is affiliated with University of Texas M.D. Anderson Cancer Center and University of Texas Medical Branch.
Education & Training
- New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1980 - 1983
- New York Medical College at St Michael's Medical CenterResidency, Internal Medicine, 1977 - 1980
- St Michael's Medical CenterInternship, Transitional Year, 1976 - 1977
- Maulana Azad Medical CollegeClass of 1976
Certifications & Licensure
- NY State Medical License 1980 - Present
- FL State Medical License 1999 - 2025
- TX State Medical License 2017 - 2025
- SC State Medical License 1989 - 2013
- GA State Medical License 1995 - 2013
- KS State Medical License Active through 2013
- NJ State Medical License 1977 - 1993
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) Start of enrollment: 2009 Mar 01
Publications & Presentations
PubMed
- Author Correction: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.Leandro C Cerchietti, Eloisi C Lopes, Shao Ning Yang, Katerina Hatzi, Karen L Bunting, Lucas A Tsikitas, Ana I Robles, Jennifer Walling, Gabriela Chiosis, Ari Melnick,...> ;Nature Medicine. 2024 Apr 3
- BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.Warren Fiskus, Jessica Piel, Michael P Collins, Murphy Hentemann, Branko Cuglievan, Christopher P Mill, Christine Birdwell, Kaberi Das, John A Davis, Hanxi Hou, Antrix...> ;Blood. 2024 Feb 16
- Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).Mill, C., Fiskus, W., DiNardo, C., Reville, P., Davis, J., Birdwell, C., Das, K., Hou, H., Takahashi, K., Flores, L., Ruan, X., Su, X., Loghavi, S., Khoury, J., Bhalla...> ;Blood Cancer Journal. 2024 Feb 5
- Join now to see all
Press Mentions
- Two Muslim Doctors Become First Donors of Plasma in Indore for Trial Treatment of Covid-19 PatientsApril 27th, 2020
- MD Anderson Research Highlights AACR 2024 Special EditionApril 6th, 2024
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
- University of Texas Medical BranchGalveston, Texas